Jason Bednar

The U.S. market seems like maybe it's had some green shoots at least in some of the data that we look at, maybe more focused on the orthodontic channel.

Are you comfortable saying demand is returning to normal across China?

How much is China impacting that? And then are you similarly making assumptions around the volume up uptick post to VBP implementation?

are there scenarios where you see that 100 basis points at risk

any updated perspective on the competitive landscape and anticipated VBP in that market as well as how or whether you plan to adjust your go-to-market and pricing strategy in light of VBP.

how would you split the volumes across those 2 buckets?

We saw higher rates, credit denials were an issue over the past year or so. You've got a new preferred financing partner in HFD

are you seeing any dislocation with doctor customers? Is that happening where you're now, call it, relatively more favorable from a cost perspective

is there a way to reduce frictions within the teen channel and really address what has been maybe a bit of a challenge or sluggish ortho environment?

it really seems like industry pricing dynamics have calmed down, at least relative to where we were last year.

talk about, Al, new fit activity across the quarter. Just what are you seeing in the data when you look at your performance versus peers

there aren't any repurchases assumed in earnings guidance for fiscal twenty six. But I thought you referenced in the supplementary PR today that you're allocating free cash entirely to to repurchase

if you could discuss how you landed on Colleen as the next chairman for the business.

it seems like the first time today where you're acknowledging that pricing industry pricing may be moderating ever so slightly

Al, I wanted to start on the MyDay, MySite reference. You think you commented you are doing early launch planning. I know it is early, but what exactly does this entail?

you did institute a price increase that took effect, I think, November 1. Can you talk about when you communicated those price increases

What's coming out of the pipeline here over the next 12 to 18 months that we can look for

Are the actions you're taking to mitigate tariffs, these are probably more in the 26 variety

Have your interactions with the FDA changed at all? And maybe sorry to pack in a couple here

what really stood out to me was that gross margin result, a really nice start to the year. Can you unpack maybe a bit some of the drivers there

do you sense the market is getting its foot back or putting back in terms of the patient traffic through offices

that $200 million benefit is pretty large. I think it's larger than a lot of us were expecting today. Shouldn't that program alone get you in that EPS CAGR range

anything you can talk about with the current state of the engagement and review with the outside consulting firms

Maybe you can give a bit more color on what you're seeing with respect to patient traffic, spending the dental office and just the confidence you have on the sustainability of these better trends

are there any adjustments to the inputs into your guidance that you're making today, even though the output isn't changing

How does tariff uncertainty from the past couple of months back up? And even if you're not seeing foot traffic changes in the office

is there something you're seeing today that gives you kind of, call it, better relative comfort on the market outlook

how you want us thinking about, under your new reporting structure, the global distribution, U.S. versus international

Can you break out by segment, cadence of launch activity, contribution to growth, and whether these are brand-new products versus relaunches

What does this big U.S. ERP change mean for your OpEx savings plans? When do you begin realizing cost savings from this switch

should we be considering any headwinds tied to just some of the weather dynamics that may or may not have impacted volumes

Can you give us a sense as to some of the things you're more excited about or expected to be more impactful

was there any benefit in your results there for dental from tariff-related price uplift

Maybe talk about the trajectory that you're seeing in that part of the business? What's driving some of that upside?

how does that compare to what you were internally expecting? It sounds like it's nicely above -- nicely above most of our models

I don't think I heard, Bryan or Wayde, a buildup or a construction of the organic growth by segment

Can you talk about what you're seeing on that front? Do you have supply visibility on chips and other critical components?

Would you be open to moving above that upper bound of $300 million if the stock remains under pressure

I got to follow the frog to some comment here. I'm going to start with cash flow guidance here. You left that unchanged

Is there a reason you wouldn't be able to maintain your typical 7% to 11% growth algorithm beyond fiscal '26

Wondering if you're willing to give maybe a similar perspective on the outlook for some of those Healthcare subsegments

you're already at $530 million in free cash flow this year. Really impressive so far

The balance there -- the cash balance there is, I think, the highest it's been in a few years

Can you talk about the capital demand environment you're seeing out there and how this order book and backlog contributes

break down, maybe again how much exposure you have here around like China-related tariffs and how much on the non-China side

it looks like share repo was a little lighter in the fourth quarter compared to the prior few quarters

Does the timing here of this trial, the retrial, affect other cases that were in line to be tried

can you talk about maybe the sustainability of these margins, especially in healthcare, as we think through some of the moving parts

Is that exclusively bioprocessing related? Are there any adjustments that you're seeing or moderation, I should probably better say on pricing

Can you specify whether -- what you've disclosed in the 10-Q this morning, whether you're a codefendent or sole defendant